Dimitrios Mavroudis
Overview
Explore the profile of Dimitrios Mavroudis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
3717
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoppe R, Winter S, Lo W, Michailidou K, Bolla M, Keeman R, et al.
NPJ Breast Cancer
. 2025 Feb;
11(1):18.
PMID: 39971965
The role of germline genetics in adjuvant aromatase inhibitor (AI) treatment efficacy in ER-positive breast cancer is poorly understood. We employed a two-stage candidate gene approach to examine associations between...
2.
Boukouris A, Kokkinakis I, Drakos E, Sfakianaki M, Tzardi M, Mavroudis D, et al.
Front Oncol
. 2025 Feb;
15:1512000.
PMID: 39935827
Metastastic disease affects up to 50% of colorectal cancer (CRC) patients and is associated with particularly poor outcomes in the presence of the V600E mutation. Herein, we report a patient...
3.
Starace M, Rapparini L, Cedirian S, Quadrelli F, Pampaloni F, Bruni F, et al.
J Eur Acad Dermatol Venereol
. 2025 Feb;
PMID: 39898721
No abstract available.
4.
Mountzios G, Lampaki S, Linardou H, Georgoulias V, Mavroudis D, Anevlavis S, et al.
Future Oncol
. 2025 Jan;
21(4):447-462.
PMID: 39785129
Background: The treatment landscape of non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly evolving with recent approvals of immunotherapies and targeted therapies. Methods: This retrospective study included 202 adults diagnosed...
5.
Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla M, et al.
Breast Cancer Res
. 2024 Dec;
26(1):189.
PMID: 39734228
Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk...
6.
Zanti M, OMahony D, Parsons M, Dorling L, Dennis J, Boddicker N, et al.
medRxiv
. 2024 Sep;
PMID: 39281752
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating...
7.
Papadaki M, Papadaki E, Chatziavraam S, Aggouraki D, Michaelidou K, Fotsitzoudis C, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272785
The Fas/Fas ligand (FasL) system is a major apoptosis-regulating pathway with a key role in tumor immune surveillance and metastasis. The expression of Fas/FasL on mammary tumor tissues holds prognostic...
8.
Messaritakis I, Koulouris A, Boukla E, Vogiatzoglou K, Lagkouvardos I, Intze E, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38792001
Background: Colorectal cancer (CRC) significantly contributes to cancer-related mortality, necessitating the exploration of prognostic factors beyond TNM staging. This study investigates the composition of the gut microbiome and microbial DNA...
9.
Lagoudaki E, Koutsopoulos A, Sfakianaki M, Papadaki C, Manikis G, Voutsina A, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38791897
To investigate the incidence and prognostically significant correlations and cooperations of LKB1 loss of expression in non-small cell lung cancer (NSCLC), surgical specimens from 188 metastatic and 60 non-metastatic operable...
10.
Thomopoulou K, Papadaki C, Monastirioti A, Koronakis G, Mala A, Kalapanida D, et al.
Front Mol Biosci
. 2024 May;
11:1413164.
PMID: 38715706
[This corrects the article DOI: 10.3389/fmolb.2021.668534.].